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One of the most relevant challenge in oncology would be the ability to deeply know tumoral genetic aspects 
through technological innovation and translational research to be finally able to personalize oncological 
treatment based not only on classical patient’s clinical characteristics but also on its tumoral genetic portrait. 
In the last few years, many studies showed that to select cancer patients for a specific drug on the basis of 
specific genetic alterations could determine the greatest potential clinical benefit for a longer time, compared 
to treatment with the classic cytotoxic chemotherapy. Thus, oncology moves from the classic "one size fits 
all" approach, which provided classic chemotherapy agents on the basis of the cancer primary site and its 
histological type, to a new classification based on the tumor molecular profile. The characterization of the 
genetic alterations of the tumors, and the understanding of the complex interaction between the molecules 
of the same network represents, therefore, the rationale on which precision medicine is based. These advances 
have been made possible by the recent development of new technologies, such as next generation sequencing 
(NGS) or massive parallel sequencing (MPS), which allow the sequencing of larger gene portions compared 
to previous technologies, with reduced times and an increase in analytical sensitivity. The potential of these 
platforms in clinical practice is linked both to the analysis of cells on tumor tissue and to the analysis of 
circulating tumor DNA (ctDNA) contained in circulating free DNA (cell free DNA, cfDNA) which can be isolated 
from peripheral blood and biological fluids (liquid biopsy), instead of neoplastic tissue. However, in complex 
tumor biology, it is not enough to identify a genetic alteration to be sure that it can represent a predictive 
factor of response or therapeutic resistance: the presence of a genetic alteration and the availability of a drug 
directed against that alteration are only preconditions for effectiveness. There are, in fact, "driver" mutations 
and "passenger" mutations; and although many neoplasms depend on a single oncogene for their growth and 
survival (according to the theory of "oncogene addiction" or "oncogene driver"), the selective pressure exerted 
by medical treatment on the network of intracellular signals can determine the hyperactivation of compensating 
pathways and alternative pathways that result in a suboptimal modulation of the target pathway. Another 
critical point that can represent an obstacle to precision medicine is tumor heterogeneity: the tumor genome 
dynamically evolves over time and accumulates genetic alterations in different cell sub-clones. This translates 
into an intratumoral heterogeneity both spatially, i.e. between the primary tumor and the metastatic sites (or, 
even, within the tumor nodule itself ), and in a temporal heterogeneity, or the bio-molecular characteristics of 
the neoplasm may vary in time. In this perspective, liquid biopsy could represent a useful tool for obtaining a 
dynamic picture of the molecular evolution of the disease. The main field of application of liquid biopsy to date 
is represented by the identification of predictive factors in patients with advanced disease and is currently used 
in clinical practice for the mutational analysis of the Epidermal Growth Factor Receptor (EGFR) and/or T790M 
gene in patients with Advanced non-small cell lung cancer (NSCLC). In particular, liquid biopsy can routinely 
replace standard tissue biopsy if tissue biopsy is technical impossible at diagnosis of advanced NSCLC or in 
patients progressing after a first (gefitinib or erlotinib) or second (afatinib) generation tyrosine-kinase inhibitors 
(TKI) in order to determine the T790M mutational status that is considered predictive for third generation TKI 
(osimertinib) efficacy. The effort of the scientific community is now to transfer the genomic and proteomic 
knowledge of basic research to clinical practice, to provide clinically relevant information for choosing a 














represent the molecular heterogeneity of the disease 
compared to the tissue biopsy, potentially containing 
tumor DNA deriving from the different areas of the 
same tumor, in the presence of tumor heterogeneity, 
it provides little information on the representativeness 
in the context of the tumor of the biomarker identified. 
Other potential limitations of liquid biopsy could 
be related to false negative (Insufficient DNA shed 
into plasma, insufficient sensitivity in older assays) or 
false positive (wide time interval between tissue and 
sample sampling, white blood cells contamination 
and tumor heterogeneity) conditions. Finally, the 
new diagnostic-therapeutic approach to neoplasms, 
which integrates clinical-pathological criteria with 
molecular analyzes, is also reflected in clinical trial 
designs: precision medicine has meant that clinical 
trials relating to new drugs with a molecular target, 
have become difficult to conduct through the classic 
designs of controlled clinical studies: the classification 
based on the molecular profile causes a segmentation 
of the neoplasms into numerous molecular subtypes, 
which include subgroups of few patients. Therefore, 
new designs of clinical trials have been developed, such 
as the "Basket" and "Umbrella trials", in which patients 
are recruited on the basis of the genetic and molecular 
characteristics of the neoplasm, with the aim of giving 
treatment only to patients potentially more responsive, 
reducing the use of ineffective and in any case toxic 
drugs, as well as the development time of new drugs and 
the associated costs. These trials resulted in two recent 
“agnostic” approval for larotrectinib and pembrolizumab 
for all patients who carried molecular alteration on NTRK 
fusion gene or who carried microsatellite instability 
respectively, irrespective of the primary tumor site. These 
represented the paradigm of a new era in oncology in 
which every patient will receive a tailored new generation 
therapy according to its own tumor genotype. Of 
course, as it is easy to imagine, these in-depth analyzes 
of the tumor genome will provide an always greater 
amount of genetic information for many of which an 
adequate cancer treatment is not yet available. It is for 
these reasons that the institutional tumor boards must 
recruit molecular biologists and pathologists which 
will therefore constitute the so-called molecular tumor 
boards whose usefulness will be essential for the correct 
interpretation of the bioinformatic data in order to 
determine the most appropriate therapeutic choice for 
every oncological patient.
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